Please login to the form below
SK Life Science
This page shows the latest SK Life Science news and features for those working in and with pharma, biotech and healthcare.
FDA clears SK Life Science’s anti-epileptic drug Xcopri
Significantly reduced the frequency of seizures at all doses studied. Korea-based SK Life Sciences has scored approval from the FDA in the US for its anti-epileptic drug Xcopri, as ... said Jeong Woo Cho, president and CEO of SK Biopharmaceuticals and SK
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Pfizer reports positive results for elranatamab in multiple myeloma
- BMS presents positive four-year results for Opdivo combination in lung cancer
- AstraZeneca to stop post-marketing study of Andexxa following early success
- Amgen’s Lumakras shows promise in phase 3 lung cancer study
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- European Commission grants two new marketing authorisations for UCB's Bimzelx
- AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants
- Janssen shares positive phase 3 results for cilta-cel in multiple myeloma
- Parkinson’s disease: past, present and future
- How to Increase Engagement During Virtual Events
- AstraZeneca to stop post-marketing study of Andexxa following early success
No results were found
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Parkinson’s disease: past, present and future
- Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
- The 17th World Congress on Controversies in Neurology
- This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
- Archetypes: Rethinking go-to-market expectations to drive commercial success
- In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
